mg vs mcg dosing
Clinical reviewer: Jacob Moore, MD · Last checked September 22, 2026
What is the difference between mg and mcg in peptide dosing?
mg vs mcg dosing refers to the difference between milligrams and micrograms, a factor of 1,000, in how peptide product strengths are labeled. NIST defines milli as one-thousandth and micro as one-millionth, so one milligram equals 1,000 micrograms. Confusing the two has caused a documented 1,000-fold overdose of a compounded drug; unapproved peptide vials carry no FDA label.
Why does mixing up mg and mcg matter?
NIST's metric-prefix table defines milli as one-thousandth (10⁻³) and micro as one-millionth (10⁻⁶) [1]. That makes one milligram equal 1,000 micrograms. Mistaking one unit for the other is not a small rounding error — it shifts a dose by three orders of magnitude, and unapproved product labels are not always written the same way as approved ones.
How do approved drug labels state strength?
Mounjaro's label states each single-dose pen or vial contains a 0.5 mL solution of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg or 15 mg of tirzepatide [2]. That is how an FDA-approved peptide drug states its strength: a specific mass, per a specific volume, on a label FDA has reviewed. Products without FDA approval have no equivalent label FDA has checked for accuracy.
How has unit confusion gone wrong?
A pediatric case report describes a 5-year-old who weighed 17.5 kg receiving 50 mg of clonidine after "a pharmacy compounding error in which milligrams were substituted for micrograms" — its title calls it "A 1000-fold overdose" [3]. FDA's Semax briefing separately records vendor-nominated strengths of "7,500 µg/mL or 1,000 µg/mL" for a product with no FDA-approved label [4], an example of the microgram-level labeling unapproved peptides use without FDA review.
Related terms
Sources
- NIST — Metric (SI) Prefixes
- Tirzepatide (Mounjaro) Prescribing Information, DailyMed
- Romano MJ, Dinh A. A 1000-fold overdose of clonidine caused by a compounding error in a 5-year-old child with attention-deficit/hyperactivity disorder. Pediatrics, 2001.
- FDA — Semax-related bulk drug substances briefing document, Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026
This entry is for education and is not medical advice. Talk with a licensed clinician about your own situation before starting, stopping, or changing any treatment.
